Seroquel found to be weight-neutral in trial

19 February 2001

AstraZeneca's antipsychotic drug Seroquel (quetiapine fumarate) does notlead to significant weight gain in patients, even after they have taken the drug for 18 months, according to new clinical data published in the current issue of the International Journal of Psychiatry in Clinical Practice. Frequently associated with some other antipsychotics, significant weight gain can affect treatment compliance and quality of life, as well as contribute to illnesses such as type 2 diabetes, cardiovascular disease and cancer, notes the company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight